Microphthalmia, Syndromic 6 (MCOPS6) Cell Models for Research

Microphthalmia, Syndromic 6 (MCOPS6) is a rare genetic disorder characterized by microphthalmia (small eyes), coloboma, and other systemic anomalies. The exact prevalence is unknown, but it is estimated to affect less than 1 in 200,000 individuals. The condition is inherited in an autosomal dominant pattern, with variable expressivity and penetrance. Clinical impact includes visual impairment, intellectual disability, and craniofacial abnormalities. Early diagnosis and management are crucial for improving quality of life. Research on MCOPS6 is vital for understanding eye development and genetic syndromes.

MCOPS6 serves as an excellent model for studying developmental biology, particularly eye morphogenesis. The disease is primarily caused by mutations in the SHROOM3 gene, which plays a key role in actin cytoskeleton organization and cell shape changes during development. Research models include patient-derived induced pluripotent stem cells (iPSCs) and gene-edited cell lines. These models help elucidate the molecular mechanisms underlying ocular development and provide platforms for drug screening. Public datasets, such as those from ClinVar and gnomAD, offer valuable genetic information for functional studies.

Although MCOPS6 is not a cancer, the molecular pathways involved are critical for development. The primary pathway is the SHROOM3-mediated actin cytoskeleton regulation. SHROOM3 interacts with Rho-associated protein kinase (ROCK) to regulate actin polymerization and cell contractility. This pathway is essential for neural tube closure and eye development. Additionally, SHROOM3 is involved in the planar cell polarity (PCP) pathway, which coordinates cell orientation and movement. Disruption of these pathways leads to developmental defects. Understanding these pathways provides insights into congenital malformations and potential therapeutic targets.

Data from ClinVar and literature. SHROOM3 mutations are the primary cause of MCOPS6.

• • Key signaling networks deregulated in MCOPS6 include:
• • Actin cytoskeleton signaling: SHROOM3-ROCK pathway, leading to altered cell shape and migration.
• • Planar cell polarity (PCP) pathway: SHROOM3 interacts with Dishevelled and Vangl2, affecting tissue polarity.
• • Wnt signaling: Crosstalk with PCP pathway, influencing eye development.
• • Rho GTPase signaling: RhoA and Rac1 are downstream effectors, regulating cytoskeletal dynamics.

These networks are crucial for proper eye morphogenesis and their disruption contributes to the phenotype.

Organoids recapitulate eye development and are valuable for drug testing and disease modeling.

• • Animal models for MCOPS6 include:
• • Shroom3 knockout mice: Exhibit microphthalmia and neural tube defects.
• • Zebrafish models: Used for high-throughput drug screening.
• • Patient-derived xenografts (PDX): Limited due to non-cancer nature, but organoid models are preferred.

These models help study disease mechanisms and test therapeutic interventions.

• • CRISPR-based gene editing has enabled the creation of isogenic cell lines with specific SHROOM3 mutations. For example:
• • SHROOM3 knockout cell lines: Generated by introducing frameshift mutations via CRISPR-Cas9.
• • SHROOM3 point mutation knock-in lines: Mimic patient-specific missense mutations.

These models are commercially available and sequence-verified, providing reliable tools for functional studies. They allow researchers to investigate the impact of specific mutations on cellular processes and screen for potential therapeutics.

• • Gene-edited cell lines are used to validate the function of SHROOM3 and its variants. For instance:
• • Knockout lines help identify downstream effectors and pathways.
• • Knock-in lines with patient mutations reveal pathogenic mechanisms.
• • CRISPR screens can identify genetic modifiers that rescue or exacerbate the phenotype.

• • Isogenic cell lines are ideal for drug screening. For example:
• • High-throughput screening of small molecules that restore actin dynamics in SHROOM3 knockout cells.
• • Testing compounds that modulate ROCK activity.
• • Resistance studies: Not applicable as MCOPS6 is not a cancer, but drug efficacy can be assessed.

CRISPR-based synthetic lethality screens can identify genes that are essential when SHROOM3 is mutated. This can reveal potential therapeutic targets and biomarkers for disease progression. For example, targeting genes that are synthetically lethal with SHROOM3 loss could provide treatment options.